2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Radiotherapy
10
Cisplatin
9
pembrolizumab
6
Surveys and Questionnaires
6
Methods
6
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
5
fludarabine
4
Papillomavirus Vaccines
4
Early Intervention, Educational
4
Cyclophosphamide
4
Brachytherapy
4
durvalumab
3
aldesleukin
3
Vaccines, Synthetic
3
Vaccines
3
Sentinel Lymph Node Biopsy
3
Radiosurgery
3
Radiation
3
Platinum
3
Palliative Care
3
Paclitaxel
3
Nivolumab
3
Indocyanine Green
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Bleomycin
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
tremelimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled